Abstract
Studies on the association between SDF1 genotype and HIV-1 susceptibility have generated inconclusive results. Therefore, we conducted a meta-analysis to summarize the findings of different studies. Articles reporting SDF1 gene polymorphisms among HIV-1 infected patients and controls were searched from PubMed up to June 2010. Odds ratios (ORs) with 95% confidence intervals (CIs) were applied to assess the association of SDF1 genotype with HIV-1 susceptibility. As a result, 13 studies with 2421 cases and 3283 controls were included in the meta-analysis. Compared with the wild-type SDF1 homozygotes, the pooled OR for SDF1 heterozygotes and SDF1-3A homozygotes were 1.07 (95% CI, 0.79-1.45), 1.38 (95% CI, 0.71-2.69) among exposed uninfected controls and 0.89 (95% CI, 0.75-1.07), 1.15 (95% CI, 0.80-1.63) among healthy controls. In conclusion, no statistically significant association between SDF1 genotype and HIV-1 susceptibility was detected in any models. Our data suggested that SDF1 genotype might have limited effect on HIV-1 susceptibility.
Keywords: SDF1, gene polymorphism, HIV-1 susceptibility, meta-analysis, cellular receptor CD4, CXC chemokine receptor, HIV-1 infection, CXCL12, homozygous individuals, homozygotes
Current HIV Research
Title: Association Between Polymorphism of SDF1 (CXCL12) Gene and HIV-1 Susceptibility: A Meta-Analysis
Volume: 9 Issue: 2
Author(s): SiJie Liu and HuanZhang Zhu
Affiliation:
Keywords: SDF1, gene polymorphism, HIV-1 susceptibility, meta-analysis, cellular receptor CD4, CXC chemokine receptor, HIV-1 infection, CXCL12, homozygous individuals, homozygotes
Abstract: Studies on the association between SDF1 genotype and HIV-1 susceptibility have generated inconclusive results. Therefore, we conducted a meta-analysis to summarize the findings of different studies. Articles reporting SDF1 gene polymorphisms among HIV-1 infected patients and controls were searched from PubMed up to June 2010. Odds ratios (ORs) with 95% confidence intervals (CIs) were applied to assess the association of SDF1 genotype with HIV-1 susceptibility. As a result, 13 studies with 2421 cases and 3283 controls were included in the meta-analysis. Compared with the wild-type SDF1 homozygotes, the pooled OR for SDF1 heterozygotes and SDF1-3A homozygotes were 1.07 (95% CI, 0.79-1.45), 1.38 (95% CI, 0.71-2.69) among exposed uninfected controls and 0.89 (95% CI, 0.75-1.07), 1.15 (95% CI, 0.80-1.63) among healthy controls. In conclusion, no statistically significant association between SDF1 genotype and HIV-1 susceptibility was detected in any models. Our data suggested that SDF1 genotype might have limited effect on HIV-1 susceptibility.
Export Options
About this article
Cite this article as:
Liu SiJie and Zhu HuanZhang, Association Between Polymorphism of SDF1 (CXCL12) Gene and HIV-1 Susceptibility: A Meta-Analysis, Current HIV Research 2011; 9(2) . https://dx.doi.org/10.2174/157016211795569113
DOI https://dx.doi.org/10.2174/157016211795569113 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Neurotoxicity of Insecticides
Current Medicinal Chemistry Induced Pluripotent Stem Cells as a Model for Therapy Personalization of Pediatric Patients: Disease Modeling and Drug Adverse Effects Prevention
Current Medicinal Chemistry Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy
Current Medicinal Chemistry CFTR Inactivation by Lentiviral Vector-mediated RNA Interference and CRISPR-Cas9 Genome Editing in Human Airway Epithelial Cells
Current Gene Therapy The Putative Adverse Effects of Bisphenol A on Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Aspects in the Pathogenesis of Nonalcoholic Steatohepatitis
Current Molecular Medicine NFAT Gene Family in Inflammation and Cancer
Current Molecular Medicine Signaling Pathways Modulating Dependence of Lung Cancer on Mutant Epidermal Growth Factor Receptor and Mechanisms of Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors
Current Pharmaceutical Design Mapping the High Throughput SEREX Technology Screening for Novel Tumor Antigens
Combinatorial Chemistry & High Throughput Screening Editorial [Is Drug Safety Dangerous?]
Current Drug Safety The Implications of Urine Drug Testing in Pain Management
Current Drug Safety Imaging Primary Brain Tumors by Single-Photon Emission Computerized Tomography (SPECT) with Technetium-99m Sestamibi (MIBI) and Tetrofosmin
Current Medical Imaging Gap Junctions as Targets for Cancer Chemoprevention and Chemotherapy
Current Drug Targets Endothelin Receptor Antagonists: A New Therapeutic Option for Improving the Outcome after Solid Organ Transplantation?
Current Vascular Pharmacology Influence of a Novel Inhibitor (UM8190) of Prolylcarboxypeptidase (PRCP) on Appetite and Thrombosis
Current Medicinal Chemistry Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase
Current Drug Targets Pediatric Immune Dysfunction and Health Risks Following Early-Life Immune Insult
Current Pediatric Reviews Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine The Importance of Guidelines in the Development and Application of Probiotics
Current Pharmaceutical Design Fractal Analysis of Epithelial-Connective Tissue Interface in Basal Cell Carcinoma of the Skin
Current Bioinformatics